Ostarine — Safety, Research, Risks & Legal Status

Not medical advice. Ostarine is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	MK-2866, enobosarm, GTx-024, S-22
Category	SARM
gtx_company	Developed by GTx Inc., a biopharmaceutical firm focused on androgen-receptor biology
investigational_status	Never approved by any regulatory agency; development discontinued in 2010s
most_studied_sarm	Among the SARMs with most published human data, though data remain limited
US legal status	Ostarine is not approved by the FDA for any use, and it is illegal to market or sell it as a dietary supplement. The FDA has warned that SARMs like ostarine are associated with serious risks including liver injury, heart attack, and stroke, and products are sold as research chemicals not for human consumption. It is prohibited at all times in sport under the WADA list.

What is Ostarine?

Ostarine is an investigational selective androgen receptor modulator (SARM) designed to stimulate androgen receptors in muscle and bone while having weaker effects on other tissues. It was studied as a potential drug candidate but never reached approval.

How it works

Ostarine is a nonsteroidal selective androgen receptor modulator with moderate selectivity for androgen receptors in muscle and bone. It binds the androgen receptor with micromolar affinity and preferentially activates tissue-specific pathways relevant to anabolism. This selectivity is intended to minimize effects on the prostate and other AR-rich tissues, though complete tissue selectivity has not been achieved in humans.

Background & history

Ostarine (MK-2866) was developed by GTx Inc. in the late 1990s as a potential treatment for muscle wasting, osteoporosis, and cachexia. It advanced to Phase II clinical trials in patients with cancer-related muscle loss and older adults with frailty. Development was ultimately discontinued before FDA approval, though it remains one of the best-characterized investigational SARMs in human literature.

What the research says

Research suggests ostarine can increase lean body mass in clinical studies of muscle wasting, and it is one of the more human-studied SARMs. However, development was discontinued and it lacks large, long-term human safety trials, so its risk profile over time is poorly characterized.

Reported effects

Reported increases in lean muscle mass in trials
Studied improvements in physical function in muscle-wasting conditions
Reported strength gains by users
Studied effects on bone in early research
Reported fat-loss effects in some studies
Studied bone-marker changes in early human work

Dosing & administration (informational)

In completed clinical studies, doses ranged from 1 to 3 mg per day in healthy volunteers and up to 3 mg daily in patients with sarcopenia over 12 weeks. Animal toxicology and early human data did not establish a safe human dose for non-clinical populations, and there is no established therapeutic window.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Reported to suppress natural testosterone production, which can disrupt the hormonal axis
Associated with cases of drug-induced liver injury and elevated liver enzymes
Can lower HDL (good) cholesterol and adversely affect lipids and cardiovascular risk markers
Long-term safety in humans is unknown because no large trials were completed
Prohibited at all times in sport under the WADA list and a common cause of failed drug tests
May cause nausea, headaches, or mild gastrointestinal effects in some users

Drug & supplement interactions

May interact with anticoagulants given possible effects on coagulation markers
Potential interactions with oral hypoglycemic agents if glucose metabolism is affected
May enhance effects of other androgenic compounds if stacked, compounding hormonal suppression
Possible interactions with hepatotoxic substances or medications given liver concerns
Limited data on interaction with lipid-lowering agents given HDL suppression risk

Who should avoid it

Avoid in patients with liver disease, elevated liver enzymes, or prior hepatotoxicity
Avoid if planning pregnancy or nursing, given lack of reproductive safety data
Avoid concurrent use with anabolic steroids or other androgenic compounds
Avoid in individuals with active cardiovascular disease or significant risk factors
Avoid if tested in sport, as WADA prohibition ensures positive results

How it is commonly combined

Ostarine is sometimes stacked with other SARMs or compounds in unregulated user communities, though such combinations multiply suppression and organ stress. No approved stacks or safe combinations exist, and multi-compound use substantially increases unknown risks and drug interactions.

Legal & regulatory. Ostarine is not approved by the FDA for any use, and it is illegal to market or sell it as a dietary supplement. The FDA has warned that SARMs like ostarine are associated with serious risks including liver injury, heart attack, and stroke, and products are sold as research chemicals not for human consumption. It is prohibited at all times in sport under the WADA list.

Quality & harm reduction

D
e
m
a
n
d
a
t
h
i
r
d
-
p
a
r
t
y
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
(
C
O
A
)
w
i
t
h
i
d
e
n
t
i
t
y
a
n
d
p
u
r
i
t
y
t
e
s
t
i
n
g
f
r
o
m
a
c
c
r
e
d
i
t
e
d
l
a
b
s
l
i
k
e
H
P
L
C
-
v
e
r
i
f
i
e
d
p
u
r
i
t
y
a
s
s
a
y
s
.
I
n
d
e
p
e
n
d
e
n
t
l
a
b
a
n
a
l
y
s
e
s
h
a
v
e
f
r
e
q
u
e
n
t
l
y
f
o
u
n
d
S
A
R
M
p
r
o
d
u
c
t
s
m
i
s
l
a
b
e
l
e
d
o
r
c
o
n
t
a
i
n
i
n
g
u
n
l
i
s
t
e
d
d
r
u
g
s
,
u
n
d
e
r
d
o
s
e
d
,
o
r
c
o
n
t
a
m
i
n
a
t
e
d
w
i
t
h
o
t
h
e
r
c
o
m
p
o
u
n
d
s
.
B
a
s
e
l
i
n
e
a
n
d
f
o
l
l
o
w
-
u
p
b
l
o
o
d
w
o
r
k
(
h
o
r
m
o
n
e
s
,
l
i
v
e
r
e
n
z
y
m
e
s
,
l
i
p
i
d
s
)
i
s
s
t
r
o
n
g
l
y
a
d
v
i
s
a
b
l
e
w
i
t
h
c
l
i
n
i
c
i
a
n
o
v
e
r
s
i
g
h
t
b
e
f
o
r
e
a
n
d
a
f
t
e
r
u
s
e
.
T
r
e
a
t
a
n
y
p
r
o
d
u
c
t
a
s
p
o
t
e
n
t
i
a
l
l
y
c
o
n
t
a
m
i
n
a
t
e
d
s
i
n
c
e
t
h
i
s
m
a
r
k
e
t
i
s
u
n
r
e
g
u
l
a
t
e
d
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Is ostarine a safe alternative to steroids?

No. It still suppresses testosterone, can affect the liver and lipids, and lacks long-term safety data, so it is not a safe substitute for anything.

What dose should I take?

We do not provide human dosing guidance. Ostarine is unapproved, and any decision belongs with a qualified clinician.

Will ostarine make me fail a drug test?

Yes. Ostarine is on the WADA prohibited list and is a frequent cause of positive tests in athletes, sometimes from contaminated supplements.

How long does it take to see effects?

In small clinical trials, measurable changes in lean mass appeared over 8-12 weeks, but individual variability is high and user reports vary widely.

Can I recover testosterone after ostarine?

Testosterone may recover after stopping, but recovery times vary and complete normalization is not guaranteed. Clinician monitoring is essential.

References & further reading

PubMed: ostarine selective androgen receptor modulator muscle wasting
PubMed: MK-2866 testosterone suppression clinical trial
FDA warning on SARMs and unapproved muscle-building drugs
WADA Prohibited List: SARMs and selective androgen receptor modulators
ClinicalTrials.gov: ostarine sarcopenia older adults